Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

DLX vs QUAD vs ENVA vs SRPT vs PRAA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DLX
Deluxe Corporation

Advertising Agencies

Communication ServicesNYSE • US
Market Cap$1.21B
5Y Perf.+15.0%
QUAD
Quad/Graphics, Inc.

Specialty Business Services

IndustrialsNYSE • US
Market Cap$400M
5Y Perf.+168.8%
ENVA
Enova International, Inc.

Financial - Credit Services

Financial ServicesNYSE • US
Market Cap$4.30B
5Y Perf.+1119.1%
SRPT
Sarepta Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2.18B
5Y Perf.-86.3%
PRAA
PRA Group, Inc.

Financial - Credit Services

Financial ServicesNASDAQ • US
Market Cap$803M
5Y Perf.-38.8%

DLX vs QUAD vs ENVA vs SRPT vs PRAA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DLX logoDLX
QUAD logoQUAD
ENVA logoENVA
SRPT logoSRPT
PRAA logoPRAA
IndustryAdvertising AgenciesSpecialty Business ServicesFinancial - Credit ServicesBiotechnologyFinancial - Credit Services
Market Cap$1.21B$400M$4.30B$2.18B$803M
Revenue (TTM)$2.13B$2.37B$3.15B$2.18B$1.24B
Net Income (TTM)$107M$27M$327M$65M$-305M
Gross Margin52.9%18.5%50.1%34.4%99.2%
Operating Margin12.2%5.0%23.5%-1.9%33.9%
Forward P/E6.6x6.3x10.5x6.9x25.9x
Total Debt$1.55B$444M$4.56B$1.04B$32M
Cash & Equiv.$311M$63M$72M$801M$104M

DLX vs QUAD vs ENVA vs SRPT vs PRAALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DLX
QUAD
ENVA
SRPT
PRAA
StockMay 20May 26Return
Deluxe Corporation (DLX)100115.0+15.0%
Quad/Graphics, Inc. (QUAD)100268.8+168.8%
Enova International… (ENVA)1001219.1+1119.1%
Sarepta Therapeutic… (SRPT)10013.7-86.3%
PRA Group, Inc. (PRAA)10061.2-38.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: DLX vs QUAD vs ENVA vs SRPT vs PRAA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ENVA leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Quad/Graphics, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. DLX also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
DLX
Deluxe Corporation
The Defensive Pick

DLX ranks third and is worth considering specifically for sleep-well-at-night and defensive.

  • Lower volatility, beta 1.09, current ratio 1.04x
  • Beta 1.09, yield 4.5%, current ratio 1.04x
  • 4.5% yield, 1-year raise streak, vs QUAD's 3.8%, (3 stocks pay no dividend)
Best for: sleep-well-at-night and defensive
QUAD
Quad/Graphics, Inc.
The Income Pick

QUAD is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 2 yrs, beta 1.03, yield 3.8%
  • Lower P/E (6.3x vs 6.9x)
  • Beta 1.03 vs SRPT's 2.02
Best for: income & stability
ENVA
Enova International, Inc.
The Banking Pick

ENVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 18.6%, EPS growth 55.9%
  • 20.3% 10Y total return vs QUAD's -23.3%
  • 18.6% NII/revenue growth vs QUAD's -9.4%
  • 9.8% margin vs PRAA's -24.6%
Best for: growth exposure and long-term compounding
SRPT
Sarepta Therapeutics, Inc.
The Value Angle

SRPT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
PRAA
PRA Group, Inc.
The Financial Play

Among these 5 stocks, PRAA doesn't own a clear edge in any measured category.

Best for: financial services exposure
See the full category breakdown
CategoryWinnerWhy
GrowthENVA logoENVA18.6% NII/revenue growth vs QUAD's -9.4%
ValueQUAD logoQUADLower P/E (6.3x vs 6.9x)
Quality / MarginsENVA logoENVA9.8% margin vs PRAA's -24.6%
Stability / SafetyQUAD logoQUADBeta 1.03 vs SRPT's 2.02
DividendsDLX logoDLX4.5% yield, 1-year raise streak, vs QUAD's 3.8%, (3 stocks pay no dividend)
Momentum (1Y)ENVA logoENVA+87.8% vs SRPT's -43.4%
Efficiency (ROA)ENVA logoENVA5.2% ROA vs PRAA's -5.9%, ROIC 10.4% vs 11.2%

DLX vs QUAD vs ENVA vs SRPT vs PRAA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DLXDeluxe Corporation
FY 2025
Checks1
54.4%$690M
Data-driven marketing solutions
22.7%$288M
Treasury management solutions
17.7%$225M
Other Payment Solutions
5.2%$66M
QUADQuad/Graphics, Inc.
FY 2025
Total Products
68.7%$1.9B
Direct Mail And Other Printed Products
22.7%$625M
Logistic Services
8.2%$226M
Other Revenues
0.3%$9M
ENVAEnova International, Inc.

Segment breakdown not available.

SRPTSarepta Therapeutics, Inc.

Segment breakdown not available.

PRAAPRA Group, Inc.
FY 2025
Total Reportable Segments
63.7%$1.1B
United States Segment
36.3%$611M

DLX vs QUAD vs ENVA vs SRPT vs PRAA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLQUADLAGGINGSRPT

Income & Cash Flow (Last 12 Months)

PRAA leads this category, winning 3 of 6 comparable metrics.

ENVA is the larger business by revenue, generating $3.2B annually — 2.5x PRAA's $1.2B. ENVA is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRAA's -24.6%. On growth, DLX holds the edge at +0.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
RevenueTrailing 12 months$2.1B$2.4B$3.2B$2.2B$1.2B
EBITDAEarnings before interest/tax$395M$196M$815M-$6M$431M
Net IncomeAfter-tax profit$107M$27M$327M$65M-$305M
Free Cash FlowCash after capex$204M$44M$1.9B$107M-$90M
Gross MarginGross profit ÷ Revenue+52.9%+18.5%+50.1%+34.4%+99.2%
Operating MarginEBIT ÷ Revenue+12.2%+5.0%+23.5%-1.9%+33.9%
Net MarginNet income ÷ Revenue+5.0%+1.2%+9.8%+3.0%-24.6%
FCF MarginFCF ÷ Revenue+9.5%+1.9%+56.2%+4.9%-7.3%
Rev. Growth (YoY)Latest quarter vs prior year+0.3%-7.7%-1.9%
EPS Growth (YoY)Latest quarter vs prior year+148.4%+18.2%+28.6%+162.6%+2.1%
PRAA leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — QUAD and PRAA each lead in 2 of 6 comparable metrics.

At 14.2x trailing earnings, QUAD trades at a 5% valuation discount to DLX's 14.9x P/E. On an enterprise value basis, PRAA's 1.7x EV/EBITDA is more attractive than ENVA's 11.3x.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
Market CapShares × price$1.2B$400M$4.3B$2.2B$803M
Enterprise ValueMkt cap + debt − cash$2.4B$781M$8.8B$2.4B$731M
Trailing P/EPrice ÷ TTM EPS14.91x14.19x14.90x-2.92x-2.68x
Forward P/EPrice ÷ next-FY EPS est.6.60x6.30x10.49x6.93x25.94x
PEG RatioP/E ÷ EPS growth rate0.28x
EV / EBITDAEnterprise value multiple6.19x3.96x11.26x1.69x
Price / SalesMarket cap ÷ Revenue0.57x0.17x1.37x0.99x0.65x
Price / BookPrice ÷ Book value/share1.79x2.97x3.40x1.91x0.79x
Price / FCFMarket cap ÷ FCF6.90x7.90x2.43x
Evenly matched — QUAD and PRAA each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

QUAD leads this category, winning 4 of 9 comparable metrics.

QUAD delivers a 25.0% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-26 for PRAA. PRAA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to QUAD's 3.45x. On the Piotroski fundamental quality scale (0–9), QUAD scores 7/9 vs SRPT's 4/9, reflecting strong financial health.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
ROE (TTM)Return on equity+16.0%+25.0%+24.9%+4.9%-26.0%
ROA (TTM)Return on assets+4.1%+2.2%+5.2%+1.9%-5.9%
ROICReturn on invested capital+9.6%+17.9%+10.4%-31.4%+11.2%
ROCEReturn on capital employed+11.8%+19.3%+13.5%-24.0%+8.7%
Piotroski ScoreFundamental quality 0–967645
Debt / EquityFinancial leverage2.26x3.45x3.41x0.91x0.03x
Net DebtTotal debt minus cash$1.2B$381M$4.5B$238M-$72M
Cash & Equiv.Liquid assets$311M$63M$72M$801M$104M
Total DebtShort + long-term debt$1.5B$444M$4.6B$1.0B$32M
Interest CoverageEBIT ÷ Interest expense3.09x2.11x79.01x-14.00x0.06x
QUAD leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ENVA leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in ENVA five years ago would be worth $46,811 today (with dividends reinvested), compared to $2,789 for SRPT. Over the past 12 months, ENVA leads with a +87.8% total return vs SRPT's -43.4%. The 3-year compound annual growth rate (CAGR) favors ENVA at 59.0% vs SRPT's -45.3% — a key indicator of consistent wealth creation.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
YTD ReturnYear-to-date+22.3%+33.6%+6.5%-2.4%+19.5%
1-Year ReturnPast 12 months+83.0%+44.4%+87.8%-43.4%+57.2%
3-Year ReturnCumulative with dividends+106.9%+197.1%+302.0%-83.6%-39.3%
5-Year ReturnCumulative with dividends-29.6%+158.1%+368.1%-72.1%-46.8%
10-Year ReturnCumulative with dividends-38.8%-23.3%+2034.9%+18.0%-32.2%
CAGR (3Y)Annualised 3-year return+27.4%+43.8%+59.0%-45.3%-15.3%
ENVA leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — QUAD and ENVA each lead in 1 of 2 comparable metrics.

QUAD is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than SRPT's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ENVA currently trades 97.6% from its 52-week high vs SRPT's 47.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
Beta (5Y)Sensitivity to S&P 5001.09x1.03x1.48x2.02x1.82x
52-Week HighHighest price in past year$32.07$8.64$176.68$44.14$22.55
52-Week LowLowest price in past year$13.61$5.01$89.00$10.42$10.25
% of 52W HighCurrent price vs 52-week peak+83.7%+88.7%+97.6%+47.1%+92.6%
RSI (14)Momentum oscillator 0–10033.050.665.463.461.2
Avg Volume (50D)Average daily shares traded368K231K227K3.0M449K
Evenly matched — QUAD and ENVA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — DLX and QUAD and PRAA each lead in 1 of 2 comparable metrics.

Analyst consensus: DLX as "Buy", QUAD as "Buy", ENVA as "Buy", SRPT as "Buy", PRAA as "Hold". Consensus price targets imply 24.5% upside for PRAA (target: $26) vs 0.6% for DLX (target: $27). For income investors, DLX offers the higher dividend yield at 4.52% vs QUAD's 3.77%.

MetricDLX logoDLXDeluxe CorporationQUAD logoQUADQuad/Graphics, In…ENVA logoENVAEnova Internation…SRPT logoSRPTSarepta Therapeut…PRAA logoPRAAPRA Group, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$27.00$8.00$199.50$24.63$26.00
# AnalystsCovering analysts67105413
Dividend YieldAnnual dividend ÷ price+4.5%+3.8%
Dividend StreakConsecutive years of raises1212
Dividend / ShareAnnual DPS$1.21$0.29
Buyback YieldShare repurchases ÷ mkt cap0.0%+2.0%+5.0%+1.1%+2.5%
Evenly matched — DLX and QUAD and PRAA each lead in 1 of 2 comparable metrics.
Key Takeaway

PRAA leads in 1 of 6 categories (Income & Cash Flow). QUAD leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallQuad/Graphics, Inc. (QUAD)Leads 1 of 6 categories
Loading custom metrics...

DLX vs QUAD vs ENVA vs SRPT vs PRAA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DLX or QUAD or ENVA or SRPT or PRAA a better buy right now?

For growth investors, Enova International, Inc.

(ENVA) is the stronger pick with 18. 6% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Quad/Graphics, Inc. (QUAD) offers the better valuation at 14. 2x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Deluxe Corporation (DLX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DLX or QUAD or ENVA or SRPT or PRAA?

On trailing P/E, Quad/Graphics, Inc.

(QUAD) is the cheapest at 14. 2x versus Deluxe Corporation at 14. 9x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 3x.

03

Which is the better long-term investment — DLX or QUAD or ENVA or SRPT or PRAA?

Over the past 5 years, Enova International, Inc.

(ENVA) delivered a total return of +368. 1%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ENVA returned +20. 3% versus DLX's -38. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DLX or QUAD or ENVA or SRPT or PRAA?

By beta (market sensitivity over 5 years), Quad/Graphics, Inc.

(QUAD) is the lower-risk stock at 1. 03β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 97% more volatile than QUAD relative to the S&P 500. On balance sheet safety, PRA Group, Inc. (PRAA) carries a lower debt/equity ratio of 3% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — DLX or QUAD or ENVA or SRPT or PRAA?

By revenue growth (latest reported year), Enova International, Inc.

(ENVA) is pulling ahead at 18. 6% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to -535. 2% for PRA Group, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DLX or QUAD or ENVA or SRPT or PRAA?

Enova International, Inc.

(ENVA) is the more profitable company, earning 9. 8% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 9. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAA leads at 33. 9% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — PRAA leads at 99. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DLX or QUAD or ENVA or SRPT or PRAA more undervalued right now?

On forward earnings alone, Quad/Graphics, Inc.

(QUAD) trades at 6. 3x forward P/E versus 25. 9x for PRA Group, Inc. — 19. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAA: 24. 5% to $26. 00.

08

Which pays a better dividend — DLX or QUAD or ENVA or SRPT or PRAA?

In this comparison, DLX (4.

5% yield), QUAD (3. 8% yield) pay a dividend. ENVA, SRPT, PRAA do not pay a meaningful dividend and should not be held primarily for income.

09

Is DLX or QUAD or ENVA or SRPT or PRAA better for a retirement portfolio?

For long-horizon retirement investors, Quad/Graphics, Inc.

(QUAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), 3. 8% yield). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QUAD: -23. 3%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DLX and QUAD and ENVA and SRPT and PRAA?

These companies operate in different sectors (DLX (Communication Services) and QUAD (Industrials) and ENVA (Financial Services) and SRPT (Healthcare) and PRAA (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DLX is a small-cap deep-value stock; QUAD is a small-cap deep-value stock; ENVA is a small-cap high-growth stock; SRPT is a small-cap high-growth stock; PRAA is a small-cap quality compounder stock. DLX, QUAD pay a dividend while ENVA, SRPT, PRAA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DLX

Income & Dividend Stock

  • Sector: Communication Services
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.8%
Run This Screen
Stocks Like

QUAD

Income & Dividend Stock

  • Sector: Industrials
  • Market Cap > $100B
  • Dividend Yield > 1.5%
Run This Screen
Stocks Like

ENVA

High-Growth Disruptor

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Net Margin > 5%
Run This Screen
Stocks Like

SRPT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
Run This Screen
Stocks Like

PRAA

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 59%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DLX and QUAD and ENVA and SRPT and PRAA on the metrics below

Revenue Growth>
%
(DLX: 0.3% · QUAD: -7.7%)
P/E Ratio<
x
(DLX: 14.9x · QUAD: 14.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.